<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0872-671X</journal-id>
<journal-title><![CDATA[Medicina Interna]]></journal-title>
<abbrev-journal-title><![CDATA[Medicina Interna]]></abbrev-journal-title>
<issn>0872-671X</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0872-671X2021000200018</article-id>
<article-id pub-id-type="doi">10.24950/o/326/20/2/2021</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Clinical Spectrum of TH/TO and NOR90 Autoantibodies in Systemic Sclerosis]]></article-title>
<article-title xml:lang="pt"><![CDATA[Espectro Clínico dos Autoanticorpos TH/TO e NOR90 na Esclerose Sistémica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cravo]]></surname>
<given-names><![CDATA[Márcia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Farinha]]></surname>
<given-names><![CDATA[Fátima]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Universitário do Porto Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Hospitalar Universitário do Porto Unidade de Imunologia Clínica ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<volume>28</volume>
<numero>2</numero>
<fpage>18</fpage>
<lpage>22</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0872-671X2021000200018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0872-671X2021000200018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0872-671X2021000200018&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Systemic sclerosis is an autoimmune disease with a large spectrum of clinical manifestations. Autoantibodies could indicate symptoms, diagnostics and establish a more appropriate treatment. The relevance of searching Th/To and NOR90 is still unknown. We aim to evaluate major manifestations and disease associations of Th/To and NOR90 autoantibodies.  Material and Methods:  Observational retrospective single-centre study, including all patients with Th/To or NOR90 autoantibodies followed in autoimmune consultation from 2018 to 2020. Absence of specific clinical information excluded patients. Demographic, clinical and diagnostical data were analysed.  Results:  In this study, female gender was the most prevalent. Cutaneous, articular, cardiopulmonary and gastrointestinal involvements were present in both autoantibodies&#8217; groups, with no renal manifestations. In 40% of both groups, systemic sclerosis diagnosis was established. No other concomitant autoantibodies were documented in 53% and 50% of anti-Th/To and anti-NOR90, respectively.  Discussion and Conclusion:  This study verified similar involvement in both groups with frequent skin and articular symptoms, more cardiopulmonary involvement in anti-Th/To group and more gastrointestinal association in anti-NOR90. Although, in this study, these autoantibodies were commonly related to systemic sclerosis, in approximately half of cases they were isolated with no other concomitant systemic sclerosis&#8217; autoantibodies, enhancing the importance of their active research when this disease is suspected.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  A esclerose sistémica é uma doença autoimune com amplo espectro clínico. Os autoanticorpos podem indiciar sintomas, diagnósticos e orientar para o tratamento mais adequado. A relevância da pesquisa do anti-Th/To e anti-NOR 90 é menos conhecida. O objetivo foi avaliar as principais manifestações clínicas e diagnósticos etiológicos associados aos anticorpos Th/To e NOR 90.  Material e Métodos:  Estudo observacional retrospetivo, envolvendo 61 doentes em seguimento na consulta externa de doenças autoimunes com os anticorpos Th/To ou NOR90 positivos em centro único, entre 2018 e 2020. Foram excluídos os doentes sem informação disponível. Os dados demográficos, manifestações clínicas e diagnósticos foram analisados com recurso a informação dos processos informáticos.  Resultados: Na amostra o género feminino foi o mais prevalente. Verificou-se envolvimento cutâneo, articular, cardiopulmonar e gastrointestinal, sem atingimento renal associado a nenhum dos autoanticorpos. Em ambos os grupos foi estabelecido diagnóstico de esclerose sistémica em 40% dos casos. Não se identificaram outros autoanticorpos concomitantes em 53% e 50% dos doentes com Th/To e NOR90, respetivamente.  Discussão e Conclusão:  Este estudo demonstrou envolvimento similar em ambos os autoanticorpos com atingimento cutâneo e articular frequentes, maior envolvimento cardiopulmonar nos doentes com anti-Th/To e gastrointestinal no grupo com anti-NOR90. Apesar de ambos se terem associado à esclerose sistémica numa percentagem não desprezível de doentes, em aproximadamente metade dos casos encontravam-se isolados, sem concomitância com outros autoanticorpos relacionados com esta doença, indiciando a relevância da sua pesquisa ativa aquando a suspeita clínica de esclerose sistémica com intuito diagnóstico.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Autoanticorpos]]></kwd>
<kwd lng="pt"><![CDATA[Esclerose Sistémica]]></kwd>
<kwd lng="pt"><![CDATA[Sinais e Sintomas.]]></kwd>
<kwd lng="en"><![CDATA[Antibodies]]></kwd>
<kwd lng="en"><![CDATA[Scleroderma, Systemic]]></kwd>
<kwd lng="en"><![CDATA[Signs and Symptoms.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leser]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Auto-Anticorpos na Esclerose Sistêmica]]></article-title>
<source><![CDATA[Rev Bras Reumatol]]></source>
<year>2004</year>
<volume>3</volume>
<page-range>215-23</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Denton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in pathogenesis and treatment of systemic sclerosis]]></article-title>
<source><![CDATA[Clin Med]]></source>
<year>2016</year>
<volume>1</volume>
<page-range>55-60</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herrick]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic Sclerosis]]></article-title>
<source><![CDATA[Brit J Hosp Med]]></source>
<year>2019</year>
<volume>9</volume>
<page-range>530-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceribelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Isailovic]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Generali]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gorlino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Palermo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of rare serum autoantibodies in rheumatic diseases a systematic literature review]]></article-title>
<source><![CDATA[J Lab Precis Med]]></source>
<year>2018</year>
<volume>3</volume>
<page-range>89</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stochmal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Czuwara]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Trojanowska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rudnicka]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antinuclear Antibodies in Systemic Sclerosis an Update]]></article-title>
<source><![CDATA[Clin Rev Allerg Immunol]]></source>
<year>2020</year>
<volume>58</volume>
<page-range>40-51</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamane]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ihn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kubo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Asano]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yazawa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2001</year>
<volume>40</volume>
<page-range>683-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceribelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cavazzana]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Franceschini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Airò]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tincani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cattaneo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma - A review]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>2071-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dagher]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Scheer]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Voit]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grummt]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lonzetti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Raymond]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[J Rheumatol]]></source>
<year>2002</year>
<volume>29</volume>
<page-range>1543-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Meirinhos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Godinho]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti- -Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with Scleroderma]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>2071-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
